규제 업데이트
2026년 9월 23일•1분 읽기
SK Biopharm Maintains Development of Epilepsy Candidate BHV‑7000 Amid FDA Partial Hold
SK Biopharm keeps its epilepsy drug BHV‑7000 development despite an FDA partial clinical hold, while negotiating a final deal with Biohaven.
규제 업데이트
2026년 9월 3일•1분 읽기
China’s Fast‑Follower Model Pressures Biotech IP Strategies
Intensifying global drug development competition highlights the need for strong patents, timed disclosures and strategic workarounds as China’s fast‑follower biotech sector accelerates patient recruitment and cuts clinical costs.
1
규제 업데이트
2026년 9월 2일•1분 읽기
Progen Begins High‑Dose Phase 1 Trial of PG‑102 for Obesity
Progen has received MFDS approval to start a high‑dose Phase 1 study of its obesity/diabetes candidate PG‑102, assessing safety, tolerability and PK/PD at Seoul St. Mary’s Hospital.
규제 업데이트
2026년 8월 31일•1분 읽기
Daewoong Pharmaceutical Starts Phase 3 Trial of Pecusclu for Maintenance Therapy in Erosive Esophagitis
Daewoong Pharma has received MFDS approval to begin a domestic Phase 3 study of its new drug Pecusclu (20 mg) aimed at securing a maintenance indication after treatment of erosive esophagitis.